ROBIN SMITH: Open Payments
NPI 1104835859 · BEREA, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$653 in 43 payments from 14 companies in 2025. Trend: 2023 $390 · 2024 $678 · 2025 $653
Food & beverage: $653
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 10 | $165 |
| ABBVIE INC. | 14 | $149 |
| GlaxoSmithKline, LLC. | 4 | $72 |
| AstraZeneca Pharmaceuticals LP | 3 | $47 |
| Novo Nordisk Inc | 2 | $34 |
| Novartis Pharmaceuticals Corporation | 1 | $30 |
| Amgen Inc. | 2 | $28 |
| ABIOMED | 1 | $24 |
| Abbott Laboratories | 1 | $21 |
| Insulet Corporation | 1 | $18 |
Products named: FANAPT, VRAYLAR, TRELEGY ELLIPTA, UBRELVY, LEQVIO, BREZTRI, OTEZLA, QULIPTA.
Industry payments across KY — which companies pay providers there.
